スタチンの使用は,閉塞性冠動脈疾患の野外患者で
Suzanne V Arnold1, John A Spertus, Fengming Tang
1MHA, St. Luke's Mid America Heart Institute, 4401 Wornall Rd, Kansas City, MO 64111, USA. suz.v.arnold@gmail.com
Circulation
|November 9, 2011
まとめ
証拠があるにもかかわらず,冠動脈疾患 (CAD) の多くの患者はスタチン療法を受けていません. 治療を受けていないCAD患者の有意な部分は,LDLコレステロールが低く,脂質管理のギャップを強調しています.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
- 公衆衛生は公衆衛生である.
背景:
- 臨床試験は,冠動脈疾患 (CAD) の患者における心血管疾患の減少におけるスタチン療法の有効性を実証しています.
- この利点は,低密度リポプロテインコレステロール (LDL-C) のレベルが100mg/dL未満の患者にも適用されます.
研究 の 目的:
- スタチン,非スタチン,およびリピド低下剤の投与頻度を評価するために,通常の診療室外ケアにおいて,阻害性CADの患者において.
- この集団における高脂血症の治療不足に関連した要因を特定する.
主な方法:
- ACCのPINNACLEレジストリから,閉塞性CADの患者38,775人を分析した.
- スタチンの処方データと非スタチンの脂質低下薬の処方データを検証した.
- 患者の人口統計,併発症,保険状況,脂質低下治療の間の研究された関連性.
主要な成果:
- 患者の77.8%がスタチンを服用し,5.3%が非スタチンの治療のみを受け,17.0%が治療を受けなかった.
- 保険の欠如はスタチン治療の欠如と関連しており,男性性,高血圧,最近の再血管化はスタチン使用と関連していた.
- 未治療患者では53.3%がLDL-C <100 mg/dLであった.
結論:
- 重要な数の阻害性CAD患者は,強力な臨床的証拠にもかかわらず,スタチンで治療が不足しているままです.
- 治療を受けていない患者の有意な割合は,LDL-Cレベルが最適以下であり,心血管疾患のリスクを減らす機会を逃したことを示しています.
- 閉塞性CADの患者に対して,改善された脂質管理戦略が必要である.
関連する概念動画
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
01:26Coronary Artery Disease IV: Preventive Measures
890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
01:27Coronary Artery Disease V: Interprofessional Care
444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
01:28Acute Coronary Syndrome IV: Interprofessional Care
522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741